Other candidates are also coming through development, including Ottimo Pharma's bifunctional antibody directed at PD-1 and VEGFR2, jankistomig, and OncoC4's PD-1xVEGF bispecific AI-08, which are ...

Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth.

The angiopoietin (ANGPT)–TIE system is crucial for the angiogenic switch in tumours, and together with vascular endothelial growth factor A (VEGFA) promotes the initiation of angiogenesis and ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.